Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Cancer Biological Therapy Market is projected to expand from USD 116.12 Billion in 2025 to USD 182.03 Billion by 2031, achieving a compound annual growth rate of 7.78%. Cancer biological therapy refers to a specialized class of treatments that utilize living organisms, their derivatives, or laboratory-engineered versions to prompt the immune system to identify and destroy malignant cells. The primary forces driving this market include the rising global incidence of cancer and a clinical shift toward precision medicine, which prioritizes targeted biological interventions over traditional non-specific treatments. As reported by the American Cancer Society, the United States was expected to see 2,001,140 new cancer cases in 2024, highlighting the substantial and expanding patient population in need of effective therapeutic options.

Despite robust demand, the market faces significant hurdles due to the prohibitive costs associated with developing and manufacturing these complex biologics. This financial barrier leads to high treatment prices that strain healthcare budgets and restrict patient access, particularly in developing regions with limited reimbursement frameworks.

Market Drivers

Accelerated regulatory pathways for new biologics have fundamentally transformed the Global Cancer Biological Therapy Market by shortening the timeline between clinical validation and patient availability. Regulatory agencies have increasingly adopted expedited review processes to speed up the entry of innovative therapies, particularly for rare and refractory cancers. This streamlined environment not only encourages pharmaceutical innovation but also ensures the rapid broadening of treatment options. For instance, the American Association for Cancer Research noted in its January 2024 'Cancer Research Catalyst' that the U.S. Food and Drug Administration approved 45 oncology drugs in 2023, demonstrating the continued momentum of market authorizations for these complex interventions.

Concurrently, the growing adoption of targeted monoclonal antibodies remains a primary driver of market revenue and clinical practice. These biologic agents have become the standard of care for numerous solid tumors, driving significant commercial growth through high utilization in both first-line and adjuvant settings. The financial scale of this segment is illustrated by the performance of leading checkpoint inhibitors; according to Merck & Co.’s 'Fourth-Quarter and Full-Year 2023 Financial Results' released in February 2024, annual sales of Keytruda rose 19% to $25.0 billion in 2023. This commercial success is supported by massive capital investment in innovation, as evidenced by Bristol Myers Squibb’s '2023 Annual Report' from March 2024, which reported a $9.3 billion investment in research and development to advance its portfolio.

Market Challenges

The high costs associated with the development and manufacturing of complex biologics represent a major obstacle to the growth of the Global Cancer Biological Therapy Market. These elevated production expenses force pharmaceutical companies to adopt premium pricing strategies to recoup their research and development investments, thereby straining healthcare budgets and insurance systems worldwide. Consequently, payers in both developed and developing regions are enforcing stricter reimbursement criteria, often delaying or denying coverage for these advanced treatments. This financial friction limits the accessible patient population and impedes the market penetration of otherwise clinically effective therapies.

According to the American Cancer Society, in 2025, the annual list price for many new cancer prescription medicines exceeded $100,000, creating a severe financial burden for patients and healthcare systems. This pricing structure directly hampers market growth by fueling high rates of financial toxicity, which frequently compels patients to forgo or discontinue necessary treatment. The resulting gap between clinical necessity and economic feasibility reduces the commercial adoption of biological therapies, preventing the market from realizing its full revenue potential.

Market Trends

The rapid adoption of oncology biosimilars is fundamentally restructuring the market by introducing cost-effective alternatives to expensive reference biologics. This trend is primarily driven by the patent expiration of major blockbuster drugs and the intensified need for healthcare systems to optimize spending without compromising clinical outcomes. By offering clinically equivalent therapeutic options at reduced prices, biosimilars are expanding patient access to essential biological treatments, particularly in resource-constrained settings. This economic shift is significant; according to the Association for Accessible Medicines' '2025 U.S. Generic & Biosimilar Medicines Savings Report' from September 2025, the biosimilars industry has generated $56.2 billion in cumulative savings for patients and the healthcare system since these agents first entered the market.

At the same time, a surge in the development of antibody-drug conjugates (ADCs) is establishing a new paradigm in targeted cancer intervention. Pharmaceutical companies are heavily investing in this modality, which combines the specificity of monoclonal antibodies with the potency of cytotoxic agents to deliver payloads directly to tumor cells while minimizing off-target toxicity. This focus has translated into rapid commercial growth for approved ADCs, validating their potential to replace conventional chemotherapy in multiple indications. According to Pfizer Inc.’s 'Second-Quarter 2025 Earnings' report from August 2025, global sales of the antibody-drug conjugate Padcev increased 38% year-over-year to reach $542 million, underscoring the high clinical demand and market uptake for these precision therapeutics.

Key Players Profiled in the Cancer Biological Therapy Market

• F Hoffmann-La Roche Ltd.
• Novartis AG
• Merck KgAa
• Amgen Inc.
• GSK PLC
• Celgene Corp
• Pfizer Inc.
• Zydus Lifesciences Ltd.
• Sun Pharmaceutical Industries Ltd.
• Bayer AG

Report Scope

In this report, the Global Cancer Biological Therapy Market has been segmented into the following categories:

Cancer Biological Therapy Market, by Product:

• Cancer Growth Blockers
• Monoclonal Antibodies
• Vaccines

Cancer Biological Therapy Market, by Distribution Channel:

• Hospitals
• Retail & Mail Order Pharmacies

Cancer Biological Therapy Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biological Therapy Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.